CCR2 regulates development of Theiler's murine encephalomyelitis virus-induced demyelinating disease

被引:21
|
作者
Bennett, Jami L. [1 ]
Elhofy, Adam [1 ]
Charo, Israel [1 ]
Miller, Stephen D. [1 ]
Dal Canto, Mauro C. [1 ]
Karpus, William J. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA
关键词
D O I
10.1089/vim.2006.0068
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease, a murine model for multiple sclerosis, involves recruitment of T cells and macrophages to the CNS after infection. We hypothesized that CCR2, the only known receptor for CCL2, would be required for TMEV-induced demyelinating disease development because of its role in macrophage recruitment. TMEV-infected SJL CCR2 knockout (KO) mice showed decreased long-term clinical disease severity and less demyelination compared with controls. Flow cytometric data indicated that macrophages (CD45(high)CD11b(+)) in the CNS of TMEV-infected CCR2 KO mice were decreased compared with control mice throughout disease. CD4(+) and CD8(+) T cell percentages in the CNS of TMEV-infected control and CCR2 KO mice were similar over the course of disease. There were no apparent differences between CCR2 KO and control peripheral immune responses. The frequency of interferon-gamma-producing T cells in response to proteolipid protein 139-151 in the CNS was also similar during the autoimmunity stage of TMEV-induced demyelinating disease. These data suggest that CCR2 is important for development of clinical disease by regulating macrophage accumulation after TMEV infection.
引用
收藏
页码:19 / 33
页数:15
相关论文
共 50 条
  • [21] Fibrin deposition in the central nervous system correlates with the degree of Theiler's murine encephalomyelitis virus-induced demyelinating disease
    Inoue, A
    Koh, CS
    Yamazaki, M
    Yanagisawa, N
    Ishihara, Y
    Kim, BS
    JOURNAL OF NEUROIMMUNOLOGY, 1997, 77 (02) : 185 - 194
  • [22] Interference with costimulation alters disease course in Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD)
    Neville, KL
    Bluestone, JA
    Miller, SD
    FASEB JOURNAL, 1998, 12 (05): : A1100 - A1100
  • [23] Ameliorating effects of anti-Dll1 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease
    Tsugane, S.
    Takizawa, S.
    Kaneyama, T.
    Yagita, H.
    Kim, B. S.
    Koh, C. -S.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S104 - S104
  • [24] The role of TIM-3 in the development of Theiler's Murine encephalomyelitis virus-induced dymyelinating disease
    Kaneyama, T.
    Tomiki, H.
    Tsugane, S.
    Ichikawa, M.
    Yagita, H.
    Kim, B.
    Koh, C. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 126 - 127
  • [25] The Level of Viral Infection of Antigen-Presenting Cells Correlates with the Level of Development of Theiler's Murine Encephalomyelitis Virus-Induced Demyelinating Disease
    Jin, Young Hee
    Kang, Hyun Seok
    Hou, Wanqiu
    Meng, Liping
    Kim, Byung S.
    JOURNAL OF VIROLOGY, 2015, 89 (03) : 1867 - 1878
  • [26] Monocyte chemotactic protein-1 plays a significant role in the development of Theiler's murine encephalomyelitis virus-induced demyelinating disease.
    Kennedy, KJ
    Karpus, WJ
    FASEB JOURNAL, 2000, 14 (06): : A1250 - A1250
  • [27] CCL2 regulates Theiler's virus-induced demyelinating disease through monocyte accumulation
    Bennett, JL
    Ransohoff, R
    Dal Canto, M
    Karpus, WJ
    FASEB JOURNAL, 2002, 16 (05): : A1062 - A1063
  • [28] The effect of pentoxifylline (PTX) on Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease
    Fushimi, T
    Inoue, A
    Koh, CS
    Yamazaki, M
    Ishihara, Y
    Kim, BS
    CELLULAR IMMUNOLOGY, 1998, 186 (02) : 140 - 146
  • [29] Cytokine messenger RNA expression in the demyelinating disease induced by theiler's murine encephalomyelitis virus
    Sato, S
    Zhang, L
    Reiner, SL
    Roos, RP
    NEUROLOGY, 1996, 46 (02) : 1080 - 1080
  • [30] Treatment of Theiler’s virus-induced demyelinating disease with teriflunomide
    Francesca Gilli
    Libin Li
    Darlene B. Royce
    Krista D. DiSano
    Andrew R. Pachner
    Journal of NeuroVirology, 2017, 23 : 825 - 838